NRF2/ARE pathway negatively regulates BACE1 expression and ameliorates cognitive deficits in mouse Alzheimer’s models
Gahee Bahn,Jong-Sung Park,Ui Jeong Yun,Yoon Jee Lee,Yuri Choi,Jin Su Park,Seung Hyun Baek,Bo Youn Choi,Yoon Suk Cho,Hark Kyun Kim,Jihoon Han,Jae Hoon Sul,Sang-Ha Baik,Jinhwan Lim,Nobunao Wakabayashi,Soo Han Bae,Jeung-Whan Han,Thiruma V Arumugam,Mark P Mattson,Dong-Gyu Jo,Thiruma V. Arumugam,Mark P. Mattson
DOI: https://doi.org/10.1073/pnas.1819541116
IF: 11.1
2019-06-04
Proceedings of the National Academy of Sciences
Abstract:Significance Considering that Alzheimer’s disease (AD) is a chronic disease progressing over a long period of time, even a slight increase of BACE1 expression may have a profound effect on Aβ accumulation. We describe a previously unknown mechanism that negatively regulates BACE1 and BACE1-AS expression and demonstrate its pivotal role in the progression of Aβ and Tau pathologies and cognitive impairment in two mouse models of AD. Given the recent failures of the clinical trials using enzymatic inhibitors of BACE1, it is critical to explore alternative approaches such as down-regulating BACE1 and BACE1-AS transcription. Our finding that NRF2 negatively regulates BACE1 and BACE1-AS therefore suggests a potential for disease modification by NRF2-activating phytochemicals or synthetic small molecules in AD.
multidisciplinary sciences